撤稿：关于COVID-19康复期血浆输注的综述：留作特殊场合的陈酿
Retraction: A review of convalescent plasma transfusion in COVID-19: Old wine reserved for special occasions.
出版信息
Lung India. 2021 Jan-Feb;38(1):105. doi: 10.4103/0970-2113.306029.
Abstract
[This corrects the article DOI: 10.4103/lungindia.lungindia_350_20].
摘要
[本文更正了文章的数字对象标识符：10.4103/lungindia.lungindia_350_20]
相似文献
1
Retraction: A review of convalescent plasma transfusion in COVID-19: Old wine reserved for special occasions.撤稿：关于COVID-19康复期血浆输注的综述：留作特殊场合的陈酿
Lung India. 2021 Jan-Feb;38(1):105. doi: 10.4103/0970-2113.306029.
2
Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group.勘误：抗纤维化药物在新冠后间质性肺疾病管理中的作用：文献综述及专家工作组报告
Lung India. 2022 May-Jun;39(3):310. doi: 10.4103/0970-2113.343593.
3
A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.一名63岁感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的女性，她发展为重症冠状病毒病2019（COVID-19）肺炎并接受了恢复期血浆治疗。
Am J Case Rep. 2020 Sep 29;21:e927662. doi: 10.12659/AJCR.927662.
4
Erratum: Demographic comparison of the first, second and third waves of COVID-19 in a tertiary care hospital at Jaipur, India.勘误：印度斋浦尔一家三级护理医院中新冠疫情第一波、第二波和第三波的人口统计学比较。
Lung India. 2023 Jan-Feb;40(1):98. doi: 10.4103/0970-2113.365497.
5
Convalescent Plasma Transfusion for the Treatment of COVID-19-Experience from Poland: A Multicenter Study.恢复期血浆输注治疗新型冠状病毒肺炎——来自波兰的经验：一项多中心研究
J Clin Med. 2020 Dec 24;10(1):28. doi: 10.3390/jcm10010028.
6
Erratum: Meropenem: A possible new culprit in eosinophilic lung diseases.勘误：美罗培南：嗜酸性粒细胞性肺病的一个可能新病因。
Lung India. 2017 Nov-Dec;34(6):581. doi: 10.4103/0970-2113.217583.
7
Erratum: How a mild influenza B infection can kill: A case of pulmonary hemorrhage.勘误：轻度乙型流感感染何以致死：一例肺出血病例
Lung India. 2017 Nov-Dec;34(6):582. doi: 10.4103/0970-2113.217584.
8
Correction: Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.更正：恢复期血浆用于预防和治疗2019冠状病毒病：一项系统评价和定量分析。
JMIR Public Health Surveill. 2021 Jun 30;7(6):e31554. doi: 10.2196/31554.
9
Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.一组波兰新冠病毒肺炎儿科患者接受恢复期血浆治疗的疗效与安全性：病例系列报告
Life (Basel). 2021 Mar 17;11(3):247. doi: 10.3390/life11030247.
10
Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design.恢复期血浆治疗 2019 冠状病毒病（COVID-19）：临床试验设计的考虑因素。
Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.
引用本文的文献
1
Plasma therapy in COVID-19: All that glitters is not gold.COVID-19中的血浆疗法：闪光的未必都是金子。
Lung India. 2021 May-Jun;38(3):297-299. doi: 10.4103/lungindia.lungindia_798_20.
2
Retraction: Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.撤回：COVID-19中的恢复期血浆疗法：黑暗中总有一线光明。
J Anaesthesiol Clin Pharmacol. 2020 Oct-Dec;36(4):573. doi: 10.4103/0970-9185.307182.
3
Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.COVID-19中的恢复期血浆疗法：黑暗中总有一线光明。
J Anaesthesiol Clin Pharmacol. 2020 Jul-Sep;36(3):419-423. doi: 10.4103/joacp.JOACP_523_20. Epub 2020 Oct 16.
本文引用的文献
1
Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.COVID-19中的恢复期血浆疗法：黑暗中总有一线光明。
J Anaesthesiol Clin Pharmacol. 2020 Jul-Sep;36(3):419-423. doi: 10.4103/joacp.JOACP_523_20. Epub 2020 Oct 16.
Zotero 插件